Unknown

Dataset Information

0

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.


ABSTRACT: Background:Uterine and ovarian carcinosarcomas (CS) are rare cancers with poor prognosis. Sacituzumab-govitecan (SG) is a new class of antibody-drug-conjugate (ADC) targeting the human-trophoblast-cell-surface marker (Trop-2) conjugated with the active metabolite of irinotecan (SN-38). We evaluated the efficacy of SG against biologically aggressive CS. Methods:Trop-2 expression was evaluated in 10 formalin-fixed-paraffined-embedded (FFPE) CS by immunohistochemistry and 9 primary CS cell-lines by flow-cytometry. One Trop-2 low/negative (SARARK14) and two Trop-2 positive (SARARK4, SARARK9) cell-lines were tested in cell-viability assays . The in vivo antitumor activity of SG was tested in xenografts models (ie, SARARK9) with strong Trop-2 expression. Results:Strong/diffuse staining was seen in 30% (3/10) of FFPE tumors and 33% (3/9) of primary CS cell lines. Trop-2 positive cell-lines (SARARK4, SARARK9) showed higher sensitivity to SG in vitro when compared to Trop-2 low/negative (SARARK14) cell lines. In xenografts, twice-weekly intravenous administration of SG for three weeks showed a significant tumor growth inhibition when compared to control, to ADC control and to the naked AB (p=0.004, p=0.007 and p=0.0007, respectively). SG significantly improved overall survival at 90 days when compared to control groups (p<0.0001). Conclusion:SG may represent a novel class of active drugs for carcinosarcomas patients overexpressing Trop-2.

SUBMITTER: Lopez S 

PROVIDER: S-EPMC7007291 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Uterine and ovarian carcinosarcomas (CS) are rare cancers with poor prognosis. Sacituzumab-govitecan (SG) is a new class of antibody-drug-conjugate (ADC) targeting the human-trophoblast-cell-surface marker (Trop-2) conjugated with the active metabolite of irinotecan (SN-38). We evaluated the efficacy of SG against biologically aggressive CS.<h4>Methods</h4>Trop-2 expression was evaluated in 10 formalin-fixed-paraffined-embedded (FFPE) CS by immunohistochemistry and 9 primary C  ...[more]

Similar Datasets

| S-EPMC6030029 | biostudies-literature
| S-EPMC4673178 | biostudies-literature
| S-EPMC7075468 | biostudies-literature
| S-EPMC5559902 | biostudies-literature
| S-EPMC7288263 | biostudies-literature
| S-EPMC10171113 | biostudies-literature
| S-EPMC9263779 | biostudies-literature
| S-EPMC7028697 | biostudies-literature
2024-10-16 | GSE278664 | GEO
| S-EPMC7650388 | biostudies-literature